News and Trends 5 Dec 2018 Llama-Inspired Antibodies Succeed in Clinical Trials and Financial Deal …into a collaboration to advance their use in cancer immunotherapy. In a phase II trial, the company’s lead antibody, efgartigimod, reduced the number of bleeding events in patients with the… December 5, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Inside Labiotech 11 Jan 2018 A Day In The Life of a Labiotech-er …and other fun projects such as planning our next Refresh events. The most interesting and creative ideas tend to flourish at this time, generally due to the excitement caused by… January 11, 2018 - 4 minutesmins - By Katherine Douglas Share WhatsApp Twitter Linkedin Email
In Depth 1 Sep 2025 Blood Cancer Awareness Month: What biotech holds in store …response. It is important to note that 21 patients died during the trial, 16 from progressive disease and five from adverse events considered unrelated to CTX130 treatment. If CTX112 is… September 1, 2025 - 13 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 28 Oct 2016 UPDATE: Immuno-Oncology Combo works on Lung Cancer Regardless of PD-L1 Type …a partial hold on the development of durvalumab in combination with tremelimumab after a number of ‘bleeding events’ unrelated to head and neck cancer were reported. As Endpoints reports, “AstraZeneca… October 28, 2016 - 2 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
2024 biotech deals tracker: the latest partnerships and M&A …regulatory events. Abeona Therapeutics (United States) and Beacon Therapeutics (United Kingdom) have signed an agreement for Beacon to evaluate the therapeutic potential of Abeona’s AAV204 capsid for ophthalmology indications. The… March 7, 2024 - 1 minutemin - By Aurore Michelin Share WhatsApp Twitter Linkedin Email
News and Trends 30 Apr 2019 Orchard’s Gene Therapy Shows Potential in Treating Patients with Beta Thalassemia …found no adverse events related to the treatment. The treatment thus met the primary aims of the trial, showing promise for the next stage of clinical development. Another company developing… April 30, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2018 Vertex Partners Oxford Genome Analysis Firm To Develop New Personalized Therapies …treatment to target the underlying cause of the disease, namely, the defective ion channel that prevents an adequate flow of fluid between cells in people with the condition. Vertex is… August 31, 2018 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2022 Ionis presents positive study results at International Symposium on amyloidosis …quality of life compared to the external placebo group. Eplontersen demonstrated a favorable safety and tolerability profile. In the study, the rate of treatment emergent adverse events (TEAEs) in the… September 7, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 The role of long-read sequencing in validating CRISPR outcomes …on each occasion. After repeating the same experiment four times, they found no consistency in outcomes, saying, “Each biological replicate differed substantially, despite a large number of unique deletion events… October 20, 2022 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2023 Alentis reports positive results from fibrosis study …adverse events were recorded. A multiple ascending dose phase 1 study is ongoing, the results of which will be reported in Q1 2023. Encouraging data for Alentis Therapeutics’ lead program… January 9, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 3 Oct 2023 Five impactful biotech companies to know in New York …The center will also create more than 400 jobs, and support a new generation of scientists, innovators, and entrepreneurs through office space, research labs, and events and programming space. The… October 3, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2024 Fighting severe epilepsies: A new era for Dravet syndrome treatment? …a reduction in convulsive seizure frequency. It also showed that zorevunersen was generally well-tolerated. However, some patients experienced adverse events like increased cerebrospinal fluid (CSF) protein levels and irritability. Despite… October 24, 2024 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email